VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM
Boston Scientific Corp · Decision date Dec 8, 2017
What did the FDA approve?
FDA records P150031 as an original PMA application. The recorded decision is approval, dated Dec 8, 2017.
FDA approval order statement
Approval for the Vercise DBS System. The device is indicated for use in bilateral stimulation of the subthalamic nucleus (STN) in the treatment of patients with moderate to advanced levodopa-responsive Parkinsons disease (PD), which is not adequately controlled with medication.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Dec 8, 2017
Regulatory record facts
- Identifier
- P150031
- Regulatory pathway
- Premarket approval application
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- Decision code
- APPR
- Decision date
- Dec 8, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P150031 received
Application receipt date recorded by FDA.
P150031 · FDA decision
APPR
P150031/S084 · Related supplement
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM
P150031/S098 · Related supplement
Vercise Genus DBS Systems; Vercise Gevia DBS Systems
P150031/S100 · Related supplement
Vercise DBS Systems
P150031/S102 · Related supplement
Vercise Deep Brain Stimulation (DBS) Systems
Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEMP150031/S084 | Boston Scientific Corp | PMA supplement | Sep 13, 2026 | FDA |
| Boston Scientific Corp | PMA supplement | Sep 22, 2026 | FDA | |
Vercise DBS SystemsP150031/S100 | Boston Scientific Corp | PMA supplement | Oct 15, 2026 | FDA |
Vercise Deep Brain Stimulation (DBS) SystemsP150031/S102 | Boston Scientific Corp | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P150031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

